This study provides a novel combination strategy for first-line treatment of follicular lymphoma, suggesting that CD20-targeted bispecific antibodies may synergize with chemoimmunotherapy to significantly extend the duration of complete response, offering critical evidence for the design of future clinical regimens.
Literature Overview
The article titled 'First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma,' published in the journal HemaSphere, systematically investigates the long-term efficacy and safety of epcoritamab combined with bendamustine and rituximab (BR) in treatment-naïve patients with follicular lymphoma (FL). Based on data from the phase 1b/2 EPCORE NHL-2 trial, the study reports follow-up results beyond three years, demonstrating that this combination induces deep and durable remissions. The rigorous study design, including high-risk patient populations, further strengthens the clinical relevance of the findings.Background Knowledge
Follicular lymphoma (FL) is a common indolent B-cell non-Hodgkin lymphoma. Although initially responsive to chemoimmunotherapy (e.g., BR regimen), most patients eventually relapse, and those with progression within 24 months (POD24) have a particularly poor prognosis. Current first-line treatments, such as R-CHOP, BR, and R2, often fail to achieve durable remissions, especially in high-risk patients. Anti-CD20 monoclonal antibodies like rituximab are widely used, but single-mechanism therapies are prone to resistance. Recently, T cell-mediated immunotherapies, particularly bispecific antibodies, have emerged as promising breakthroughs. Epcoritamab, a subcutaneously administered CD3×CD20 bispecific antibody, bridges T cells and malignant B cells, inducing potent cytotoxic effects. However, its potential in combination with conventional chemotherapy as first-line therapy remains insufficiently validated. This study addresses this unmet clinical need by exploring whether epcoritamab combined with BR can overcome the limitations of current treatments, improve complete response rates, and prolong progression-free survival.
Research Methods and Experiments
The study enrolled 25 patients with previously untreated FL who received six cycles of epcoritamab in combination with BR, followed by up to two years of epcoritamab monotherapy as maintenance. The primary endpoint was investigator-assessed overall response rate (ORR), with key secondary endpoints including complete response (CR) rate, duration of complete response (DOCR), progression-free survival (PFS), and overall survival (OS). All patients underwent CD20 expression testing to confirm eligibility. Efficacy was regularly monitored using PET-CT scans, with pseudoprogression ruled out according to Lugano and LYRIC criteria. Pharmacodynamic analyses were performed using flow cytometry to track dynamic changes in peripheral B cells, T cell subsets, and NK cells, alongside monitoring of immunoglobulin levels (IgG, IgA, IgM).Key Conclusions and Perspectives
Research Significance and Prospects
This study provides important direction for drug development, demonstrating that CD20-targeted bispecific antibodies are not only suitable for relapsed/refractory patients but can also be advanced into first-line therapy, where they synergize effectively with conventional regimens. For clinical monitoring, long-term follow-up data support dynamic immunoglobulin level assessment in patients achieving CR to prevent infectious complications. Furthermore, the success of this regimen suggests future exploration of broader combination strategies, such as sequential use with immune checkpoint inhibitors or CAR-T therapy, to further extend treatment intervals.
Conclusion
This study establishes epcoritamab in combination with BR as a highly effective and well-tolerated first-line treatment option for patients with treatment-naïve, high-tumor-burden follicular lymphoma. With over three years of follow-up, the 96% CR rate and 87% three-year CR maintenance rate significantly outperform historical controls, with consistent performance even in high-risk patients. The regimen achieves synergistic antitumor effects through dual targeting of CD20—leveraging both rituximab’s ADCC activity and epcoritamab’s T cell activation. Although infection risk is elevated, the absence of severe neurotoxicity or high-grade CRS indicates manageable safety. From bench to bedside, this study introduces a new paradigm in disease modeling: layering T cell immunotherapy onto conventional chemotherapy can dramatically enhance both depth and durability of response. Future research should include randomized controlled trials to confirm its advantages over standard regimens and explore biomarkers to optimize patient selection, enabling truly personalized therapy and reshaping the care landscape for follicular lymphoma.
